Syndax Pharmaceuticals, Inc. ( NASDAQ: SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia October 24, 2025 2:30 PM EDT ...
Reimagining pharmacy benefits modular empowers health systems with technology-driven control, transparency, and improved patient care management.
TipRanks on MSN
Syndax confirms FDA approves second indication for Revuforj
Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Revuforj for the treatment of relapsed or ...
Machine learning models accurately predict which psoriatic and axial spondyloarthritis patients will respond to treatment, ...
In a Phase II trial, 23 percent of patients achieved complete remission plus complete remission with partial hematologic recovery on Revuforj.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback